2020PubMed@AikoHIRAKI:re33213530 JSONTXT

Annnotations TAB JSON ListView MergeView

Covid19_manual_annotation

Id Subject Object Predicate Lexical cue ForCovid19 all_replicate correct/standard/original word details tao:has_database_id typo
111 2610-2632 Disease denotes hereditary xanthinuria history|exclusion_criteria MESH:C562584
113 2728-2744 Disease denotes hypersensitivity exclusion_criteria MESH:D004342
114 2748-2759 Chemical denotes favipiravir drug MESH:C462182
115 2831-2839 Species denotes patients Tax:9606
116 2852-2870 Disease denotes hepatic impairment exclusion_criteria MESH:D008107
122 3164-3172 Species denotes patients Tax:9606
123 3196-3207 Status_of_Care denotes in-patients
124 3380-3388 Species denotes Patients Tax:9606
125 3427-3434 Trial denotes GETAFIX abbreviation
127 3529-3540 Chemical denotes favipiravir drug MESH:C462182
128 3548-3556 Species denotes patients Tax:9606
129 3588-3599 Chemical denotes favipiravir drug MESH:C462182
130 3658-3666 Species denotes patients Tax:9606
131 3726-3737 Chemical denotes favipiravir drug MESH:C462182
132 3783-3791 Species denotes Patients Tax:9606
133 3829-3836 Trial denotes GETAFIX abbreviation
135 3991-3998 Trial denotes GETAFIX abbreviation
136 4024-4035 Chemical denotes favipiravir drug MESH:C462182
137 4073-4081 Species denotes patients Tax:9606
140 4291-4303 Species denotes participants Tax:9606
141 4330-4335 Die denotes death MESH:D003643
142 4405-4413 Species denotes Patients Tax:9606
143 4612-4620 Species denotes patients Tax:9606
144 4708-4720 Disease denotes hypertension history|inclusion_criteria MESH:D006973
145 4752-4759 Disease denotes obesity inclusion_criteria MESH:D009765
147 4988-5000 Species denotes participants Tax:9606
148 5124-5132 Species denotes patients Tax:9606
149 5159-5166 Trial denotes GETAFIX abbreviation
150 5273-5281 Species denotes patients Tax:9606
151 5368-5376 Species denotes patients Tax:9606
152 5490-5498 Species denotes patients inclusion_criteria Tax:9606
153 5586-5594 Species denotes patients inclusion_criteria Tax:9606
154 5750-5757 Trial denotes GETAFIX abbreviation
155 5818-5826 Species denotes patients Tax:9606
79 226-237 Chemical denotes favipiravir drug MESH:C462182
81 281-290 Disease denotes infection MESH:D007239
82 294-302 Species denotes patients Tax:9606
83 471-482 Chemical denotes favipiravir drug MESH:C462182
85 601-610 Disease denotes infection MESH:D007239
86 637-648 Chemical denotes favipiravir drug MESH:C462182
88 737-745 Species denotes patients Tax:9606
89 902-910 Species denotes Patients Tax:9606
90 1005-1016 Chemical denotes favipiravir drug MESH:C462182
91 1080-1092 Species denotes PARTICIPANTS Tax:9606
92 1124-1132 Species denotes patients Tax:9606
94 1286-1294 Species denotes patients Tax:9606
95 1318-1329 Status_of_Care denotes in-patients
96 1472-1480 Species denotes Patients Tax:9606
98 1623-1633 Species denotes SARS-CoV-2 Tax:2697049
T101 1525-1539 Age denotes Age 16 or over inclusion_criteria
T102 1687-1722 Index denotes WHO COVID-19 ordinal severity scale inclusion_criteria
T103 1666-1667 Grade denotes 1 inclusion_criteria
T104 1750-1762 Status_of_Care denotes Asymptomatic inclusion_criteria
T105 1798-1821 Status_of_Care denotes Symptomatic Independent inclusion_criteria
T106 1823-1852 Status_of_Care denotes Symptomatic assistance needed inclusion_criteria
T107 1876-1890 Therapy denotes oxygen therapy
T108 1900-1905 Percent denotes >=10% inclusion_criteria
T109 1974-1987 Index denotes ISARIC4C risk inclusion_criteria
T110 2300-2308 Therapy denotes dialysis notCovid19
T111 2312-2327 Therapy denotes haemofiltration notCovid19
T112 2363-2386 Condition denotes child bearing potential exclusion_criteria
T114 2748-2759 Chemical denotes favipiravir
T115 2765-2776 Chemical denotes metabolites
T116 2780-2794 Chemical denotes any excipients drug
T127 3448-3466 Therapy denotes standard treatment
T128 3856-3874 Therapy denotes standard treatment
T129 3603-3608 Timing denotes day 1
T13 1240-1254 Disease denotes co-morbidities inclusion_criteria|comorbidity
T130 3612-3618 Dosage denotes 3600mg
T131 3647-3656 Timing denotes days 2-10
T132 3741-3746 Amount denotes 800mg
T133 3747-3755 Interval denotes 12 hours
T134 3772-3774 Count denotes 18
T135 3620-3626 Amount denotes 1800mg
T137 3627-3635 Interval denotes 12 hours
T142 4210-4251 Index denotes WHO COVID 10 point ordinal severity scale
T144 4854-4889 Index denotes WHO COVID-19 ordinal severity score inclusion_criteria
T145 4339-4346 Duration denotes 60 days inclusion_criteria
T146 4903-4906 Grade denotes 1/2 inclusion_criteria
T148 4679-4684 Age denotes 16-50 inclusion_criteria
T149 4685-4690 Age denotes 51-70 inclusion_criteria
T150 4691-4694 Age denotes 71+ inclusion_criteria
T152 4742-4745 Index denotes BMI inclusion_criteria abbreviation MESH:D015992
T153 4745-4748 Value denotes >30 inclusion_criteria
T154 5120-5123 Number denotes 302 inclusion_criteria
T155 5174-5177 Number denotes 151 inclusion_criteria
T156 5201-5204 Number denotes 151 inclusion_criteria
T157 5424-5429 Number denotes eight inclusion_criteria
T158 5440-5445 Number denotes eight inclusion_criteria
T159 8-23 Therapy denotes Early Treatment
T160 1234-1239 Condition denotes major
T161 4051-4069 Therapy denotes standard treatment
T163 2900-2916 Severity denotes Child-Pugh grade exclusion_criteria
T164 2917-2918 wGrade denotes A exclusion_criteria
T165 2922-2925 Gene denotes AST exclusion_criteria Gene:2805
T166 2929-2932 Gene denotes ALT exclusion_criteria Gene:2875
T167 2935-2942 Times denotes 5 x ULN exclusion_criteria
T170 2958-2965 Times denotes 3 x ULN exclusion_criteria
T171 2976-2985 Chemical denotes Bilirubin exclusion_criteria MESH:D001663
T172 2988-2993 Times denotes 2xULN exclusion_criteria
T173 3110-3133 Chemical denotes concomitant medications comorbidity|drug|exclusion_criteria
T174 3718-3722 Dose denotes dose
T175 3706-3717 Type denotes maintenance
T176 79-87 Disease denotes COVID-19 MESH:D000086382
T177 272-280 Disease denotes COVID-19 t MESH:D000086382
T178 592-600 Disease denotes COVID-19 MESH:D000086382
T179 690-698 Disease denotes COVID-19 MESH:D000086382
T180 1163-1171 Disease denotes COVID-19 MESH:D000086382
T181 1598-1606 Disease denotes COVID-19 MESH:D000086382
T182 1643-1651 Disease denotes COVID-19 MESH:D000086382
T183 1783-1791 Disease denotes COVID-19 MESH:D000086382
T184 4087-4095 Disease denotes COVID-19 MESH:D000086382
T185 3037-3045 Disease denotes COVID-19 MESH:D000086382
T186 353-369 Therapy denotes standard of care MESH:D059039
T187 248-257 BecomeReduce denotes effective
T189 136-163 TrialDesign denotes randomised controlled trial
T190 957-973 Index denotes primary endpoint
T191 919-929 TrialDesign denotes randomised
T193 848-858 TrialDesign denotes randomised
T194 3389-3399 TrialDesign denotes randomised
T195 3792-3802 TrialDesign denotes randomised
T196 4280-4290 TrialDesign denotes randomised
T197 4422-4432 TrialDesign denotes randomised
T198 5141-5151 TrialDesign denotes randomised
T199 799-809 TrialDesign denotes open label
T2 67-78 Timing denotes early stage
T200 827-830 Number denotes two
T201 940-943 Number denotes two
T202 835-840 TrialDesign denotes phase
T203 844-847 TrialDesign denotes III
T204 835-843 TrialDesign denotes phase II
T205 811-825 TrialDesign denotes parallel group
T206 870-873 Ratio denotes 1:1
T207 4433-4436 Ratio denotes 1:1
T208 1053-1071 Therapy denotes standard treatment
T209 1022-1040 Therapy denotes standard treatment
T210 1225-1233 Negative denotes no prior
T211 1186-1189 Negative denotes not
T212 1266-1284 TrialDesign denotes multi-centre trial
T213 1334-1345 Status_of_Care denotes outpatients
T214 1351-1356 Number denotes three
T215 1734-1747 TrialDesign denotes randomisation
T217 1669-1670 Grade denotes 2 inclusion_criteria
T219 1672-1673 Grade denotes 3 inclusion_criteria
T221 1678-1679 Grade denotes 4 inclusion_criteria
T222 1873-1875 Negative denotes no
T223 1914-1919 Die denotes death inclusion_criteria MESH:D003643
T224 2068-2076 Negative denotes Negative
T225 2146-2161 Chemical denotes oral medication drug|inclusion_criteria
T227 2423-2446 Condition denotes child bearing potential exclusion_criteria
T228 2404-2419 Sex denotes female partners exclusion_criteria
T230 2460-2463 Negative denotes not
T231 2486-2508 Method denotes contraceptive measures
T232 2946-2949 Gene denotes AST exclusion_criteria Gene:2805
T233 2953-2956 Gene denotes ALT exclusion_criteria Gene:2875
T234 2997-3015 Period denotes More than 96 hours exclusion_criteria
T236 3051-3057 Trial denotes sample
T237 3229-3234 Number denotes three
T238 3212-3223 Status_of_Care denotes outpatients
T239 3144-3162 TrialDesign denotes multi-centre trial
T241 3471-3479 Disease denotes COVID-19 MESH:D000086382
T242 3407-3423 TrialDesign denotes experimental arm
T243 3093-3109 Negative denotes contra-indicated
T245 3071-3077 Negative denotes Unable
T247 3081-3092 Negative denotes discontinue
T248 3580-3584 Dose denotes dose
T249 3810-3821 TrialDesign denotes control arm
T251 3879-3887 Disease denotes COVID-19 MESH:D000086382
T252 4012-4020 BecomeReduce denotes efficacy
T253 4444-4456 TrialDesign denotes experimental
T255 4724-4740 Disease denotes currently obsess comorbidity|inclusion_criteria MESH:D006973
T257 4697-4704 Timing denotes history
T258 4708-4720 Disease denotes hypertension
T259 4259-4274 Period denotes 15 +/- 48 hours
T261 4909-4912 Grade denotes 3/4 inclusion_criteria
T262 4936-4947 TrialDesign denotes No blinding
T263 5185-5196 TrialDesign denotes control arm
T264 5212-5228 TrialDesign denotes experimental arm
T265 5326-5344 Trial denotes PK and PD sampling
T266 5394-5406 Trial denotes this testing
T267 5602-5618 TrialDesign denotes experimental arm
T268 5455-5466 Trial denotes This option
T269 5486-5489 Target denotes all
T27 1854-1866 Status_of_Care denotes Hospitalized inclusion_criteria
T270 5981-5988 Database denotes EudraCT
T271 5921-5979 Database denotes European Union Drug Regulating Authorities Clinical Trials
T272 5990-5998 Database denotes Database
T273 4144-4162 Therapy denotes standard treatment
T274 4163-4168 Condition denotes alone
T275 243-247 PositiveRegulation denotes more
T276 1072-1077 Condition denotes alone
T277 990-1001 PositiveRegulation denotes superiority
T278 1094-1104 Trial denotes This trial
T279 1256-1260 Trial denotes This
T281 1927-1931 Species denotes they Tax:9606
T282 4472-4475 TrialDesign denotes arm
T283 4464-4475 TrialDesign denotes control arm
T284 5415-5422 Number denotes sixteen inclusion_criteria
T29 1935-1955 Status_of_Care denotes admitted to hospital inclusion_criteria
T30 2077-2086 Condition denotes pregnancy inclusion_criteria
T38 2798-2804 Severity denotes Severe no-comorbidity
T39 2805-2819 Disease denotes co-morbidities comorbidity|exclusion_criteria MESH:D015897
T42 2845-2851 Severity denotes severe no-comorbidity
T6 312-323 Timing denotes early stage
T64 4789-4795 Duration denotes 7 days inclusion_criteria
T65 4840-4844 Sex denotes male inclusion_criteria
T66 4845-4851 Sex denotes female inclusion_criteria
T72 5430-5435 Sex denotes males inclusion_criteria
T73 5446-5453 Sex denotes females inclusion_criteria
T75 5521-5532 Status_of_Care denotes in hospital inclusion_criteria
T76 0-7 Area denotes Glasgow
T77 1357-1364 Area denotes Glasgow
T78 1447-1454 Area denotes Glasgow
T79 3235-3242 Area denotes Glasgow
T80 3325-3332 Area denotes Glasgow
T81 42-49 Trial denotes GETAFIX abbreviation
T82 182-189 Trial denotes GETAFIX abbreviation
T83 785-792 Trial denotes GETAFIX abbreviation
T84 4968-4975 Trial denotes GETAFIX abbreviation
T85 5697-5704 Trial denotes GETAFIX abbreviation
T86 5891-5898 Trial denotes GETAFIX abbreviation
T87 6129-6136 Trial denotes GETAFIX abbreviation
T88 28-40 Chemical denotes Favirpiravir drug Favipiravir t
T89 55-61 Age denotes adults inclusion_criteria
T91 1190-1198 Condition denotes pregnant exclusion_criteria
T94 1202-1215 Condition denotes breastfeeding inclusion_criteria
T95 2343-2356 Condition denotes breastfeeding exclusion_criteria
T97 2331-2339 Condition denotes Pregnant exclusion_criteria
T98 1118-1123 Age denotes adult inclusion_criteria
104 2093-2098 Species denotes women inclusion_criteria Tax:9606
105 2162-2170 Species denotes Patients Tax:9606
106 2250-2266 Disease denotes Renal impairment exclusion_criteria MESH:D007674
108 2388-2393 Sex denotes women exclusion_criteria
110 2448-2451 Sex denotes men exclusion_criteria
R22 T193 T206 of_a randomised,1:1
R67 T114 T116 - favipiravir,any excipients
R68 113 114 to hypersensitivity,favipiravir
R69 113 T114 to hypersensitivity,favipiravir
R21 T202 T200 of_a phase,two
R1 136 135 is_a favipiravir,GETAFIX
R10 79 T275 is_a favipiravir,more
R100 T268 T265 coreference This option,PK and PD sampling
R11 T275 T187 is_a more,effective
R12 T187 T177 is_a effective,COVID-19
R13 T186 T275 against standard of care,more
R14 T177 T6 of_a COVID-19,early stage
R15 T81 T76 abbreviation GETAFIX,Glasgow
R16 T81 T159 abbreviation GETAFIX,Early Treatment
R17 T81 T88 abbreviation GETAFIX,Favirpiravir
R18 T176 T2 of_a COVID-19,early stage
R19 T202 T203 - phase,III
R2 T161 135 is_a standard treatment,GETAFIX
R20 T204 T200 of_a phase II,two
R23 T208 T276 has_status standard treatment,alone
R24 90 T277 is_a favipiravir,superiority
R25 T209 T277 is_a standard treatment,superiority
R26 T208 T277 against standard treatment,superiority
R27 T211 T94 is_a not,breastfeeding
R28 T98 92 is_a adult,patients
R29 92 T278 of_a patients,This trial
R3 135 T252 is_a GETAFIX,efficacy
R30 92 T91 has_status patients,pregnant
R31 92 T94 has_status patients,breastfeeding
R32 T210 T13 is_a no prior,co-morbidities
R33 T13 T160 has_status co-morbidities,major
R34 92 T13 has_status patients,co-morbidities
R35 T278 T83 coreference This trial,GETAFIX
R36 T279 T83 coreference This,GETAFIX
R37 T212 T214 coreference multi-centre trial,three
R38 94 95 has_status patients,in-patients
R39 94 T213 has_status patients,outpatients
R4 T252 T184 is_a efficacy,COVID-19
R40 T98 T101 coreference adult,Age 16 or over
R41 T180 92 has_status COVID-19,patients
R42 T180 T102 of_a COVID-19,WHO COVID-19 ordinal severity scale
R43 T103 T104 has_status 1,Asymptomatic
R44 T217 T105 has_status 2,Symptomatic Independent
R45 T219 T106 has_status 3,Symptomatic assistance needed
R46 T221 T27 has_status 4,Hospitalized
R47 T222 T107 is_a no,oxygen therapy
R48 T103 T102 is_a 1,WHO COVID-19 ordinal severity scale
R49 T217 T102 is_a 2,WHO COVID-19 ordinal severity scale
R5 T273 T252 against standard treatment,efficacy
R50 T219 T102 is_a 3,WHO COVID-19 ordinal severity scale
R51 T221 T102 is_a 4,WHO COVID-19 ordinal severity scale
R52 T107 T27 with oxygen therapy,Hospitalized
R53 104 T30 has_status women,pregnancy
R54 T224 T30 is_a Negative,pregnancy
R55 T108 T109 is_a >=10%,ISARIC4C risk
R56 95 T29 coreference in-patients,admitted to hospital
R57 T223 T109 of_a death,ISARIC4C risk
R59 T281 T29 has_status they,admitted to hospital
R6 T273 T274 has_status standard treatment,alone
R60 T281 T108 of_a they,>=10%
R61 108 T112 has_status women,child bearing potential
R63 110 T227 has_status men,child bearing potential
R64 T231 110 using contraceptive measures,men
R65 T230 T231 is_a not,contraceptive measures
R66 T114 T115 - favipiravir,metabolites
R7 T184 137 has_status COVID-19,patients
R70 T243 T173 is_a contra-indicated,concomitant medications
R71 129 T248 of_a favipiravir,dose
R72 T129 T248 of_a day 1,dose
R73 T135 T248 of_a 1800mg,dose
R74 T137 T248 of_a 12 hours,dose
R75 T175 T174 of_a maintenance,dose
R76 131 T174 of_a favipiravir,dose
R77 T132 T174 of_a 800mg,dose
R78 T133 T174 of_a 12 hours,dose
R79 T134 T174 of_a 18,dose
R8 T177 82 has_a COVID-19,patients
R80 T131 T174 of_a days 2-10,dose
R81 T174 T242 of_a dose,experimental arm
R82 T248 T242 of_a dose,experimental arm
R83 T128 T249 of_a standard treatment,control arm
R84 125 T242 of_a GETAFIX,experimental arm
R85 133 T249 of_a GETAFIX,control arm
R86 T253 T282 - experimental,arm
R87 T258 T255 - hypertension,currently obsess
R88 144 T257 of_a hypertension,history
R89 148 T154 of_a patients,302
R9 81 82 has_a infection,patients
R90 T263 T155 of_a control arm,151
R91 T264 T156 of_a experimental arm,151
R92 T72 T157 of_a males,eight
R93 T73 T158 of_a females,eight
R94 151 T157 of_a patients,eight
R95 151 T158 of_a patients,eight
R96 T267 151 of_a experimental arm,patients
R97 151 T75 has_status patients,in hospital
R98 T266 T265 coreference this testing,PK and PD sampling
R99 T267 149 of_a experimental arm,GETAFIX